Flow cytometry によるBromodeoxyuridine(BrdU) /DNA同時解析法の応用 2.制癌剤感受性試験への応用のための基礎的研究

Abstract

MBT-2細胞に種々の条件で各種制癌剤を接触させ, その細胞動態と標識細胞のサイクル進行に及ぼす効果を解析した.この方法で得られた解析結果を, 同条件下で行ったcolony assayのsurvival curveと比較検討した.1) ADRによる標識細胞のサイクル進行遅延およびG2M期細胞集積の大きさと, 抗腫瘍効果との間には相関があった.したがって本法を用いることにより, IC90程度の抗腫瘍効果を早期に推測し得る可能性がある.2) VCRでは標識細胞のサイクル進行に及ぼす作用やG2M期単峰性集積作用と, 抗腫瘍効果との間には相関がなかった.3) CDDPによる標識細胞のサイクル進行遅延およびS期, G2M期への細胞集積の大きさと, 抗腫瘍効果との間には高濃度領域では相関があった.しかし, 低濃度領域での判定には困難が伴った

We developed a new method to rapidly measure the effectiveness of certain anticancer drugs by analyzing their effects on cell kinetics and cell cycle progression of labeled cells using simultaneous flow cytometric BrdU/DNA analysis. Three anticancer drugs, adriamycin (ADR), vincristine (VCR), and cisplatin (CDDP) were tested using the cultured cell line (MBT-2) originated from FANFT-induced mouse bladder tumor. The effects of these drugs were compared with percent colony survivals calculated by colony assay. The anticancer effects (IC90 levels) of ADR and CDDP could be determined by analyzing the effect of the drug on cell kinetics and cell cycle progression using the aforementioned method. However, in the case of VCR no relationship was found between the effect of the drug on cell kinetics and its anticancer effectiveness. Therefore, we must search for a better parameter for VCR, such as the inhibition rate of BrdU uptake.